Form 10-Q Esperion Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Northland Upgrades Esperion Therapeutics (ESPR) to Market Perform. 'Potential Resolution of DSE Litigation as Catalysts'
August 1, 2023 2:01 PM EDTNorthland Capital Markets analyst Carl Byrnes upgraded Esperion Therapeutics (NASDAQ: ESPR) from Underperform to Market Perform with a price target of $2.00 (from $1.00).
The analyst comments "We are adjusting our rating to MP as we believe sNDA approvals in both the... More
